Clinical trials
Alzheimer Disease or Associated Disorder clinical trials
Below are recruiting alzheimer disease or associated disorder clinical trials, each written for real people, not researchers. We’re tracking 1,808 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06688968Recruiting
Music, thinking, and memory in Parkinson's and Alzheimer's
This study looks at how music engagement affects thinking and memory in people with Parkinson's or Alzheimer's disease. It may help researchers understand how music can support brain health as we age.
Montpellier, HéraultAges 60 years+ - NCT07213700Recruiting
Alzheimer's disease long-term study
This study follows people with Alzheimer's disease over time to learn more about the condition and improve future care. It is an observational study, meaning participants receive their usual care while researchers collect information.
MelbourneAges 18 years+ - NCT07118137Recruiting
Memory loss in Alzheimer's disease study
This study looks at how memory changes over time in people with Alzheimer's or mild memory problems. It uses advanced brain scans to understand the disease better.
Trondheim, TrønderlagAges 55 years+ - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06824142Recruiting
Testing a 3D clock for Alzheimer's time orientation
This study tests a 3D tool (like a special clock) to help people with Alzheimer's keep track of time. You may be eligible if you have mild to moderate Alzheimer's and trouble with time orientation.
ChampcueilAges 65 years+ - NCT06731842Enrolling by invitation
Brain scans and blood tests for Alzheimer's disease
This study uses a special brain scan (PET imaging) and blood tests to look for early signs of Alzheimer's and other brain diseases. It aims to improve how we detect and understand these conditions.
StockholmAges 30–85 - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Birmingham, AlabamaAges 55–80 - NCT04079179RecruitingPhase 2
Cobimetinib for difficult Langerhans cell and similar disorders
This Phase 2 trial studies cobimetinib, a medicine that targets a specific growth-and-signal pathway, to treat stubborn (refractory or worsening) Langerhans cell histiocytosis and related disorders. It may help shrink active disease or stop disease from progressing.
Phoenix, ArizonaAges Any age - NCT05934188Recruiting
Study how gut signals relate to brain aging and diseases
This study looks at how the gut may influence the brain in normal aging and conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis. It may help researchers understand new ways to measure or treat these brain changes over time.
Venice-Lido, VeniceAges 20–90 - NCT05655650Recruiting
Finding blood or brain markers in Alzheimer’s disease
This study looks for “biomarkers,” or measurable signs, that help identify Alzheimer’s disease. It may help doctors diagnose Alzheimer’s more accurately by comparing people with Alzheimer’s to others where the diagnosis is different.
Hong Kong, Hong HongAges 20 years+ - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT03653156Recruiting
Aging and brain study for mild memory loss and dementia
This study checks how age affects memory and thinking, and compares people with mild memory problems, Alzheimer’s disease types, vascular dementia, and healthy controls. You may help researchers understand brain changes using thinking tests, MRI scans, and blood or spinal fluid tests.
Hefei, AnhuiAges 18 years+ - NCT03657732Recruiting
Study of inherited Alzheimer’s genes in families
This study looks at people from families with inherited Alzheimer’s disease, including those who may be cognitively normal. It uses medical checkups and brain/nerve tests to better understand Alzheimer’s risk and symptoms in families with specific gene changes.
Hefei, AnhuiAges 18 years+ - NCT02649985RecruitingPhase 1/Phase 2
PET brain scan study for several brain and mood conditions
This early-phase study uses PET and MRI brain scans to better understand brain changes in multiple sclerosis, Alzheimer’s disease, and other neurological or mood conditions. The goal is to test whether these scans can show disease-related differences and guide future treatments.
Boston, MassachusettsAges 18–85 - NCT06672237RecruitingPhase 3
Study of NTLA-2001 for hereditary ATTR amyloidosis with nerve damage
This study is testing a new gene-silencing treatment called NTLA-2001 for people with hereditary ATTR amyloidosis that causes nerve damage. It works by stopping the body from making a faulty protein that builds up and harms nerves.
Buenos AiresAges 18–85 - NCT07169630RecruitingPhase 1
PET scan study for Alzheimer's or mild cognitive impairment
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
Bethesda, MarylandAges 50–100 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT02800395Recruiting
Study links brain changes to diet and blood markers in Alzheimer’s
This study looks at how diet-related and blood “stress” markers relate to how thinking and memory decline over time in people with Alzheimer’s. It may help researchers find useful biomarkers to better track progression and guide future care.
Pierre-BéniteAges 55 years+ - NCT03082755RecruitingPhase 4
Study sleep agitation and restless legs in Alzheimer’s patients
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
Austin, TexasAges 55 years+ - NCT05984524Recruiting
Gamma music therapy for mild Alzheimer's disease
This study tests whether a specially designed music intervention can help people with mild Alzheimer's disease. You listen to music with a gamma frequency beat, which may improve brain function and memory.
Boston, MassachusettsAges 50–95 - NCT05194787Recruiting
Online tests to spot early Alzheimer’s changes
This study looks at whether online motor (movement) and thinking tasks can detect early changes related to Alzheimer’s disease. You may be able to take part if you’re over 50 and do not already have a diagnosis of dementia.
Hobart, TasmaniaAges 50 years+ - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85
Hear when a new Alzheimer Disease or Associated Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer disease or associated disorder?
- Yes. Clin2 currently lists 1,808 recruiting alzheimer disease or associated disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer disease or associated disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer disease or associated disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.